Synopsis: Though Gland Pharma, Akums Medicine, and Kwality Prescribed drugs all reported spectacular Q1 FY27 outcomes, what every firm has deliberate for the longer term is what actually units them aside. This can be a comparability of their pipelines, capability, and contracted progress.
Gland Pharma, Akums Medicine and Prescribed drugs, and Kwality Prescribed drugs all reported double-digit progress for the quarter ended June 30, 2026, making it a busy outcomes week for the pharmaceutical CDMO sector in India.
The extra intriguing query for buyers is which firm has essentially the most credible progress runway forward, although all three exceeded income and revenue targets. This largely depends upon what every firm counts as a “pipeline.”
Gland Pharma has the strongest seen high-value pipeline
In Q1 FY27, Gland’s CDMO income elevated 20% YoY to ₹891.5 crore; nevertheless, the extra vital issue is what lies forward. Eight ANDAs and 7 505(b)(2) filings are among the many fifteen merchandise underneath co-development; commercialisation is anticipated to begin in FY28.
With six merchandise already launched and three extra pending approval, Gland’s in-house advanced injectable pipeline will not be solely extra quite a few than its opponents, however additionally it is getting nearer to monetisation.
In spite of everything merchandise are commercialised, its CDMO partnership with a significant worldwide pharmaceutical firm has an estimated $90–100 million in annualised income potential. The know-how switch is anticipated to be completed in two years, and income will begin to move in 2029.
As well as, Gland has submitted 21 Prepared-to-Use infusion bag merchandise, acquired approval for 18 of them, and is at present creating 11 extra, with an estimated $644 million US market alternative. When mixed, these present Gland with a number of totally different future progress layers as an alternative of a single pipeline that’s reliant on a single product class.
Akums has the strongest capacity-led runway, however its pipeline is much less explicitly quantified
With Q1 CDMO income of ₹964 crore, up 18.6% YoY, Akums’ CDMO enterprise already makes up 82.6% of whole income. Extra importantly, capability utilisation reached 50% attributable to double-digit CDMO quantity progress, indicating vital headroom earlier than present infrastructure is absolutely utilised.
The ₹56 crore Oriflame manufacturing acquisition provides two amenities overlaying skincare, color cosmetics, and wellness, and administration has said clearly that it intends so as to add extra CDMO purchasers to those items. Akums can also be aggressively rising the addressable CDMO alternative.
Regardless that the ahead pipeline isn’t quantified in the identical contract-by-contract element Gland affords, its manufacturing base already covers a wide range of dosage types, together with oral solids, injectables, lyophilised vials, and pre-filled syringes, giving it breadth.
Kwality has essentially the most fascinating “build-the-pipeline” story
Kwality operates primarily as a generic out-licensing and provide participant, with pure CDMO at present under-represented. Its benefit lies in utilizing its aggressive submitting engine (200 filings in FY26) and R&D capabilities as a hook to transition into advanced biologics and oncology CDMO engagements.
With greater than 1,000 formulations, greater than 700 regulatory filings, and greater than 100 purchasers in LATAM, MENA, Europe, Asia, and Africa, the corporate’s submitting exercise elevated from 75 in FY23 to 200 in FY26. Kwality has established an annual capability of 300 million injectable items alongside biologics, with utilization in its devoted oncology block at present operating between 60% and 70%
In distinction to Gland’s or Akums’ more moderen pipelines, the corporate is notably creating end-to-end biologics growth capabilities particularly to help future biosimilar and biologics CDMO engagements.
The expansion prospects rely on what an investor values
With 15 co-development merchandise, 3 advanced merchandise awaiting approval, 11 RTU merchandise underneath growth, and a $90–100 million potential CDMO contract with an outlined income begin date, Gland stands out when it comes to seen, near-term commercialisation.
Akums’ benefit is in scale and utilisation headroom: its double-digit quantity progress, 50% capability utilisation, and 82.6% CDMO income publicity enable it to develop inside its present clientele earlier than requiring new capability.
Of the three, Kwality’s alternative is essentially the most developmental: 200 filings in FY26, greater than 700 cumulative filings, and investments in oncology capabilities and complicated biologics contribute to future CDMO progress. Nonetheless, in contrast to Gland, its presentation doesn’t embrace a financial quantity for a selected CDMO backlog.
The choice for buyers is extra about time horizon than which firm is “forward”: Gland for short-term contracted upside, Akums for capacity-driven scale, and Kwality for a longer-dated wager on biologics and complexity.
Disclaimer: The views and funding ideas expressed by funding specialists/broking homes/score businesses on tradebrains.in are their very own, and never that of the web site or its administration. Investing in equities poses a danger of monetary losses. Buyers should subsequently train due warning whereas investing or buying and selling in shares. Commerce Brains Applied sciences Personal Restricted or the creator usually are not responsible for any losses prompted because of the choice primarily based on this text. Please seek the advice of your funding advisor earlier than investing.
